ClinicalTrials.gg
CompletedNCT02584504ODYSSEY-NIPPONUpdated Jan 23, 2019Results posted

Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin

A Phase 3 interventional study of Alirocumab and Placebo in Hypercholesterolemia, sponsored by Sanofi. Completed at 30 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2019-01-23.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.

Enrollment
20th of 43
163 · median 107
Started
2015
with 2 others
Phase 3
20 of 43
none open now
Registered
29th of 43
by date
Lead sponsor
28 of 43
Sanofi

Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 20th largest by enrollment, is one of 3 that started in 2015, is one of 20 in phase 3, and was the 29th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About alirocumab

alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing alirocumab in Hypercholesterolemia, or all of them as a file.
02

Study summary

Primary Objective:

To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab administration as add-on therapy to non-statin lipid modifying therapy (LMT) including diet therapy alone or the lowest strength of statin in comparison with placebo after 12 weeks of treatment in participants with hypercholesterolemia.

Secondary Objective:

  • To evaluate the effect of two treatment regimens of alirocumab on other lipid parameters: apolipoprotein B (Apo-B), non-high-density lipoprotein cholesterol (non HDL-C), total cholesterol (TC), lipoprotein (a) (Lp[a]), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), and apolipoprotein A-1 (Apo A-1).
  • To evaluate the safety and tolerability of alirocumab administration.
  • To evaluate the development of anti-alirocumab antibodies.
  • To evaluate the pharmacokinetic and pharmacodynamic profiles of alirocumab administration.
  • To evaluate the long-term safety in participants receiving open-label alirocumab administration.
Read the detailed description

The duration of study per participant was approximately 71 weeks consisting of a run-in period (4 weeks), a screening period (3 weeks), a double-blind treatment period (12 weeks), and an open-label treatment period (52 weeks).

03

Conditions studied

  • Hypercholesterolemia

Keywords

  • Non-statin LMT
  • Low dose statin
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants with hypercholesterolemia (heFH or non-FH) receiving non statin LMTs or the lowest strength of statin.

Exclusion criteria

Exclusion criteria:

  • LDL-C \<100 mg/dL (\<2.59 mmol/L) at the screening visit (Week -3) in participants with heFH or in participants with non-FH who have a history of documented coronary heart disease.
  • LDL-C \<120 mg/dL (\<3.10 mmol/L) at the screening visit (Week -3) in participants with non-FH participants who had a history of documented diseases or other risk factors classified as primary prevention category III as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.
  • Not on a stable dose of LMT (including diet therapy alone) in the run-in period or the screening period.
  • Fasting serum TGs >400 mg/dL (>4.52 mmol/L) at the screening period.
  • Systolic blood pressure (BP) >160 mmHg or diastolic BP >100 mmHg at the run-in visit (Week -7) or the screening visit (Week -3) or the randomization visit (Week 0).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Experimental
    Alirocumab 150 mg Q4W

    Double-blind treatment period(DBTP):participants received Alirocumab 150 mg subcutaneous injection every 4 week(Q4W) alternating with placebo(for alirocumab)Q4W added to lowest-strength statin therapy(atorvastatin 5 mg daily),stable non-statin LMT/diet therapy alone for 12weeks. Participants completed DBTP,entered open-label treatment period(OLTP),received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg every 2 weeks(Q2W) at Week 24(OLTP:Week 12),when targeted LDL-C level at Week 20 not achieved as Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012:1) ≥100 mg/dL(2.59 mmol/L) in heterozygous familial hypercholesterolemia (heFH) participants/non-familial hypercholesterolemia (non-FH)participants with history of documented coronary heart disease;2) ≥120 mg/dL(3.10 mmol/L)in non-FH participants with history of documented diseases/other risk factors as categorized in primary prevention category III)

    Drug: Alirocumab · Drug: Placebo · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone

  • Experimental
    Alirocumab 150 mg Q2W

    In DBTP, participants received Alirocumab 150 mg subcutaneous (SC) injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg daily), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to Japan Atherosclerosis Society(JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.

    Drug: Alirocumab · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone

  • Placebo comparator
    Placebo Q2W

    In DBTP, participants received Placebo (for alirocumab) SC injection Q2W added to lowest-strength statin therapy (atorvastatin 5 mg), stable non-statin LMT or diet therapy alone for 12 weeks. Participants who completed DBTP were entered in OLTP and received alirocumab 150 mg Q4W up to additional 52 weeks. Alirocumab dose up-titrated to 150 mg Q2W at Week 24 (Week 12 of OLTP), when targeted LDL-C levels at Week 20 were not achieved i.e. LDL-C ≥100 mg/dL (2.59 mmol/L) or ≥120 mg/dL (3.10 mmol/L) according to JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012.

    Drug: Placebo · Drug: Atorvastatin · Drug: Non-statin Lipid-Modifying Therapy · Other: Diet Alone

Interventions

  • Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

    Also known as: SAR236553, REGN727

  • DrugPlacebo

    Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

  • Atorvastatin 5 mg tablet orally.

  • DrugNon-statin Lipid-Modifying Therapy

    Ezetimibe, Bezafibrate or Fenofibrate at stable dose as background therapy.

  • OtherDiet Alone

    Stable cholesterol-lowering diet as background therapy.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis

    Adjusted Least-squares (LS) means and standard errors at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were used in the model (ITT analysis).

    Time frame: From Baseline to Week 12

Secondary outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

    Time frame: From Baseline to Week 12

  2. Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment and assigning a weight of 0.5 for Week 10 and 12 time points.

    Time frame: From Baseline to Week 12

  3. Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection) and assigning a weight of 0.5 for Week 10 and 12 time points.

    Time frame: From Baseline to Week 12

  4. Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  5. Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data at from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

    Time frame: From Baseline to Week 12

  6. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  7. Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis

    Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

    Time frame: From Baseline to Week 12

  8. Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  9. Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis

    Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heterozygous familiar hypercholesterolemia (heFH) participants or non-familial hypercholesterolemia (non-FH) participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: Up to Week 12

  10. Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis

    Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heFH participants or non-FH participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

    Time frame: Up to Week 12

  11. Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis

    Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.

    Time frame: From Baseline to Week 12

  12. Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  13. Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis

    Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

  14. Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis

    Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

    Time frame: From Baseline to Week 12

Other outcomes

  1. Percent Change From Baseline in Calculated LDL-C at Week 20, 24, 36, 48 and 64 -OLTP Analysis

    Time frame: Baseline, Weeks 20, 24, 36, 48 and 64

07

Results

Posted May 7, 2018

Participant flow

The study was conducted at 30 active centers in Japan. Overall 241 participants were screened between 30 November 2015 and 19 October 2016, of whom 78 were screen failures and 163 were randomized. Screen failures were mainly due to exclusion criteria met.

Double-blind Treatment
Participant flow — Double-blind Treatment
MilestoneAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Started545356
Itt population545356
Mitt population545356
Safety population545356
Completed545155
Not completed021
Withdrew: Participant withdrew consent001
Withdrew: Adverse event010
Withdrew: Family matter010
Open-label Treatment
Participant flow — Open-label Treatment
MilestoneAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Started545155
Treated545054
Completed524747
Not completed248
Withdrew: Participant withdrew consent004
Withdrew: Adverse event223
Withdrew: Physician decision010
Withdrew: Entered but not treated011

Outcome measures

PrimaryPercent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis

Adjusted Least-squares (LS) means and standard errors at Week 12 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were used in the model (ITT analysis).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12- Intent to Treat (ITT) Analysis-43.8 ± 2.2-70.1 ± 2.3-4.3 ± 2.2
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Least square (ls) mean difference: -39.5 · 97.5% CI -46.5 to -32.4Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -65.8 · 97.5% CI -72.9 to -58.7Alirocumab 150 mg Q2W vs. Placebo
  • Alirocumab 150 mg Q4W vs Alirocumab 150 mg Q2W · Ls mean difference: -26.3 · 95% CI -32.5 to -20.0Alirocumab 150 mg Q4W group vs Alirocumab 150 mg Q2W
SecondaryPercent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Calculated LDL-C at Week 12- On-Treatment Analysis-43.4 ± 2.1-70.1 ± 2.2-2.8 ± 2.1
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -40.6 · 97.5% CI -47.4 to -33.8Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -67.4 · 97.5% CI -74.2 to -60.5Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment and assigning a weight of 0.5 for Week 10 and 12 time points.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12: ITT Analysis-54.2 ± 1.9-69.9 ± 1.9-3.7 ± 1.9
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -50.5 · 97.5% CI -56.6 to -44.5Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -66.2 · 97.5% CI -72.3 to -60.1Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection) and assigning a weight of 0.5 for Week 10 and 12 time points.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Calculated LDL-C to Averaged Week 10 to 12- On-Treatment Analysis-54.0 ± 1.9-69.9 ± 1.9-2.6 ± 1.9
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -51.4 · 97.5% CI -57.4 to -45.4Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -67.3 · 97.5% CI -73.3 to -61.3Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Apolipoprotein B (Apo-B) at Week 12: ITT Analysis-32.2 ± 2.0-57.9 ± 2.0-6.0 ± 2.0
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -26.2 · 97.5% CI -32.5 to -19.9Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -51.9 · 97.5% CI -58.3 to -45.5Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data at from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Apo-B at Week 12- On-Treatment Analysis-31.8 ± 2.0-58.0 ± 2.0-4.6 ± 1.9
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -27.2 · 97.5% CI -33.5 to -20.9Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -53.4 · 97.5% CI -59.7 to -47.1Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 12: ITT Analysis-36.2 ± 2.0-61.1 ± 2.0-4.9 ± 2.0
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -31.3 · 97.5% CI -37.7 to -25.0Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -56.2 · 97.5% CI -62.5 to -49.8Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis

Adjusted LS means and standard errors at Week 12 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Non-HDL-C at Week 12- On-treatment Analysis-35.9 ± 1.9-61.1 ± 2.0-3.5 ± 1.9
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -32.4 · 97.5% CI -38.6 to -26.3Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -57.6 · 97.5% CI -63.8 to -51.4Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 12- ITT Analysis-25.8 ± 1.5-44.7 ± 1.6-3.3 ± 1.5
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -22.5 · 97.5% CI -27.4 to -17.6Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: -41.4 · 97.5% CI -46.4 to -36.5Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis

Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heterozygous familiar hypercholesterolemia (heFH) participants or non-familial hypercholesterolemia (non-FH) participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 were obtained from multiple imputation approach for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis
percentage of participantsAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- ITT Analysis85.296.214.3
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Odds ratio (or): 61.2 · 97.5% CI 13.9 to 268.9Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Odds ratio (or): 281.4 · 97.5% CI 33.3 to 2382.2Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis

Calculated LDL-C goal was defined as calculated LDL-C \<100 mg/dL (2.59 mmol/L) for heFH participants or non-FH participants who had a history of documented CHD, or \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 12 from multiple imputation approach including available post-baseline on-treatment data from Week 4 to Week 12 (i.e. up to 21 days after last double-blind injection).

Time frame:
Up to Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis
percentage of participantsAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percentage of Participants Reaching Calculated LDL-C Goal at Week 12- On-Treatment Analysis85.296.210.8
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Odds ratio (or): 102.8 · 97.5% CI 19.0 to 556.8Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Regression, Logistic · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Odds ratio (or): 500.8 · 97.5% CI 47.9 to 5230.9Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis

Adjusted means and standard errors at Week 12 were obtained from multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment were included in the imputation model.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Lipoprotein (a) at Week 12: ITT Analysis-31.7 ± 3.3-49.6 ± 3.31.3 ± 3.3
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Regression, Robust · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Adjusted mean difference: -32.9 · 97.5% CI -43.4 to -22.5Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Regression, Robust · p = <0.0001 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Adjusted mean difference: -50.9 · 97.5% CI -61.5 to -40.3Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12- ITT Analysis7.7 ± 1.89.9 ± 1.82.0 ± 1.8
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Mixed Models Analysis · p = 0.0241 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: 5.7 · 97.5% CI 0.0 to 11.3Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Mixed Models Analysis · p = 0.0022 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Ls mean difference: 7.8 · 97.5% CI 2.1 to 13.5Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis

Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Fasting Triglycerides (TGs) at Week 12: ITT Analysis-0.6 ± 3.7-18.0 ± 3.8-6.4 ± 3.7
Statistical analysis
  • Alirocumab 150 mg Q4W vs Placebo Q2W · Regression, Robust · p = 0.2645 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Adjusted mean difference: 5.9 · 97.5% CI -5.9 to 17.7Alirocumab 150 mg Q4W vs. Placebo
  • Alirocumab 150 mg Q2W vs Placebo Q2W · Regression, Robust · p = 0.0299 (Threshold for significance at 0.025 level for Bonferroni adjustment.) · Adjusted mean difference: -11.6 · 97.5% CI -23.5 to 0.4Alirocumab 150 mg Q2W vs. Placebo
SecondaryPercent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis

Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 12 regardless of status on- or off-treatment.

Time frame:
From Baseline to Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis
percent changeAlirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2W
Percent Change From Baseline in Apolipoprotein A-1 (Apo A-1) at Week 12: ITT Analysis6.8 ± 1.69.1 ± 1.72.9 ± 1.6
Other pre-specifiedPercent Change From Baseline in Calculated LDL-C at Week 20, 24, 36, 48 and 64 -OLTP Analysis
Time frame:
Baseline, Weeks 20, 24, 36, 48 and 64
Reported as:
Mean · Percent change
Percent Change From Baseline in Calculated LDL-C at Week 20, 24, 36, 48 and 64 -OLTP Analysis
Percent changeAlirocumab 150mgQ4W/Up Q2W(After Alirocumab 150mgQ4W in DBTP)Alirocumab 150mgQ4W/Up Q2W(After Alirocumab 150mgQ2W in DBTP)Alirocumab 150mg Q4W/Up Q2W (After Placebo Q2W in DBTP)
Week 20-42.1 ± 20.1-47.8 ± 24.2-45.5 ± 20.5
Week 24-39.7 ± 20.4-46.0 ± 20.0-47.8 ± 21.7
Week 36-49.2 ± 19.4-51.5 ± 19.6-56.2 ± 18.8
Week 48-48.6 ± 21.6-53.9 ± 17.6-57.8 ± 17.4
Week 64-44.3 ± 22.8-55.2 ± 17.5-58.1 ± 19.6

Adverse events

Collected over All Adverse Events (AEs) were collected from signature of the informed consent form up to the end of study (up to Week 64) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-blind Treatment Period: Placebo Q2W0/56 (0%)1/56 (1.8%)14/56 (25%)
Double-blind Treatment Period: Alirocumab 150 mg Q4W0/54 (0%)1/54 (1.9%)11/54 (20.4%)
Double-blind Treatment Period: Alirocumab 150 mg Q2W1/53 (1.9%)2/53 (3.8%)13/53 (24.5%)
Open-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W0/158 (0%)12/158 (7.6%)72/158 (45.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventDouble-blind Treatment Period: Placebo Q2WDouble-blind Treatment Period: Alirocumab 150 mg Q4WDouble-blind Treatment Period: Alirocumab 150 mg Q2WOpen-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W
Metastases to stomachNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/560/541/530/158
Non-small cell lung cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/560/541/530/158
AnaemiaBlood and lymphatic system disorders0/560/541/530/158
Dizziness posturalNervous system disorders0/560/541/530/158
Loss of consciousnessNervous system disorders0/560/541/530/158
Interstitial lung diseaseRespiratory, thoracic and mediastinal disorders0/561/540/530/158
Angina unstableCardiac disorders1/560/540/530/158
Coronary artery stenosisCardiac disorders0/560/540/532/158
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/560/540/531/158
Pituitary tumour benignNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/560/540/531/158
Most frequent other events
Most frequent other events
EventDouble-blind Treatment Period: Placebo Q2WDouble-blind Treatment Period: Alirocumab 150 mg Q4WDouble-blind Treatment Period: Alirocumab 150 mg Q2WOpen-label Treatment Period: Alirocumab 150 mg Q4W/Up Q2W
Viral upper respiratory tract infectionInfections and infestations9/568/548/5354/158
Non-cardiac chest painGeneral disorders1/560/544/533/158
FallInjury, poisoning and procedural complications3/560/541/5311/158
PharyngitisInfections and infestations0/563/540/535/158
DizzinessNervous system disorders3/560/540/532/158
Back painMusculoskeletal and connective tissue disorders0/560/541/538/158

Baseline characteristics

Baseline population included all randomized participants.

Age, Continuous
Age, Continuous(years)Alirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2WTotal
Mean62.6 ± 9.863.6 ± 10.464.6 ± 10.063.6 ± 10.1
Sex: Female, Male
Sex: Female, Male(Participants)Alirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2WTotal
Female21201960
Male333337103
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2WTotal
Asian545356163
Calculated LDL-C in mg/dL
Calculated LDL-C in mg/dL(mg/dL)Alirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2WTotal
Mean154.2 ± 59.5149.2 ± 31.1149.4 ± 32.6150.9 ± 42.8
Calculated LDL-C in mmol/L
Calculated LDL-C in mmol/L(mmol/L)Alirocumab 150 mg Q4WAlirocumab 150 mg Q2WPlacebo Q2WTotal
Mean3.993 ± 1.5413.865 ± 0.8063.870 ± 0.8443.909 ± 1.109
08

Study locations

30 sites
  • Investigational Site Number 392028
    Ageo-Shi, Japan
  • Investigational Site Number 392007
    Chuo-Ku, Japan
  • Investigational Site Number 392029
    Chuo-Ku, Japan
  • Investigational Site Number 392014
    Fukui-Shi, Japan
  • Investigational Site Number 392023
    Hachioji-Shi, Japan
  • Investigational Site Number 392013
    Itoshima-Shi, Japan
  • Investigational Site Number 392010
    Kanazawa-Shi, Japan
  • Investigational Site Number 392024
    Kasuga-Shi, Japan
  • Investigational Site Number 392004
    Kawanishi-Shi, Japan
  • Investigational Site Number 392015
    Kitakyushu-Shi, Japan
  • Investigational Site Number 392005
    Komatsu-Shi, Japan
  • Investigational Site Number 392032
    Matsudo-Shi, Japan
  • Investigational Site Number 392017
    Matsumoto-Shi, Japan
  • Investigational Site Number 392003
    Mito-Shi, Japan
  • Investigational Site Number 392018
    Morioka-Shi, Japan
  • Investigational Site Number 392009
    Moriya-Shi, Japan
  • Investigational Site Number 392006
    Nagoya-Shi, Japan
  • Investigational Site Number 392011
    Nagoya-Shi, Japan
  • Investigational Site Number 392019
    Nagoya-Shi, Japan
  • Investigational Site Number 392025
    Nagoya-Shi, Japan
  • Investigational Site Number 392027
    Osaka-Shi, Japan
  • Investigational Site Number 392030
    Sakura-Shi, Japan
  • Investigational Site Number 392016
    Shinagawa-Ku, Japan
  • Investigational Site Number 392001
    Shinjuku-Ku, Japan
  • Investigational Site Number 392008
    Shinjuku-Ku, Japan
  • Investigational Site Number 392012
    Shizuoka-Shi, Japan
  • Investigational Site Number 392002
    Suita-Shi, Japan
  • Investigational Site Number 392031
    Suita-Shi, Japan
  • Investigational Site Number 392020
    Toyonaka-Shi, Japan
  • Investigational Site Number 392022
    Yao-Shi, Japan
09

References and documents

Publications

  • Teramoto T, Kondo A, Kiyosue A, Harada-Shiba M, Ishigaki Y, Tobita K, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale. Lipids Health Dis. 2017 Jun 17;16(1):121. doi: 10.1186/s12944-017-0513-7. PubMed 28623954 ↗
  • Teramoto T, Kiyosue A, Ishigaki Y, Harada-Shiba M, Kawabata Y, Ozaki A, Baccara-Dinet MT, Sata M. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON. J Cardiol. 2019 Mar;73(3):218-227. doi: 10.1016/j.jjcc.2018.10.004. Epub 2018 Nov 30. PubMed 30509509 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Apr 2017, 16 months.

Results were first posted in May 2018, 1 year 1 month after primary completion.

Of 122 industry-sponsored phase 3 interventional studies under Hypercholesterolemia, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 16 months is below that.

Counting every sponsor, half of 125 studies reached it within 18 months; a quarter within 10 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2015
First posted
Oct 22, 2015
StartActual
Nov 30, 2015
Primary completionActual
Apr 5, 2017
CompletionActual
Jan 9, 2018
Results first posted
May 7, 2018
Last update
Jan 23, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02584504
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Oct 22, 2015
Start date
Nov 30, 2015
Primary completion
Apr 5, 2017
Completion
Jan 9, 2018
Results posted
May 7, 2018
Last update
Jan 23, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alirocumab

Start the discussion